Ōtolith Labs

12/02/2025

As a member of the Vestibular Disorders Association (VEDA) Industry Advisory Council, Otolith is proud to partner with an organization that bridges science, clinical care, and patient advocacy to improve the lives of people living with dizziness, vertigo, and imbalance.

As the year comes to a close, we’re reflecting on VeDA’s meaningful impact: advancing research, raising awareness, and connecting patients with trusted information and expert care.

Their work is vital, and its reach grows when our community comes together to give.

This , we invite our colleagues, friends, and partners to join us in supporting VeDA’s mission. Your donation helps fund education, advocacy, and hope for the millions affected by vestibular disorders worldwide.

Donate here: https://secure.vestibular.org/forms/givingtuesday2025

10/22/2025

What an inspiring weekend exhibiting at !

The Otolith booth was buzzing with excitement as we connected with hundreds of clinicians, researchers, and innovators who share our passion for advancing care.

It was an honor to meet so many leaders across the vestibular field and see the genuine enthusiasm and curiosity surrounding our breakthrough technology and pivotal clinical study results.

A huge thank you to the American Academy of Otolaryngology—Head and Neck Surgery for organizing such an impactful meeting that brings together the brightest minds in the field to share research, collaborate, and inspire innovation.

Every year, this conference leaves us inspired, energized, and more committed than ever to pushing the field forward. We’re proud to be part of that progress.

See you next year!

08/19/2025

Did you know? Vestibular migraine (VM) affects 2.7% of U.S. adults, with women accounting for 64% of diagnosed cases.

In addition to common VM episode triggers, women face added challenges tied to hormonal fluctuations. The menstrual cycle, pregnancy, and menopause are all known to trigger or intensify VM episodes, compounding an already debilitating condition.

Yet despite its widespread impact, treatment options remain limited.

At Otolith, we’re working hard to change that by developing a noninvasive therapeutic device that targets the vestibular system, bringing relief to those living with chronic vestibular conditions.

Source: https://pubmed.ncbi.nlm.nih.gov/30020261/

06/25/2025

Wilson Sonsini was a tremendous success!

“Otolith proudly announced the launch of our $15M investment opportunity at earlier this month. This news follows our pivotal trial data, paving the way for our upcoming De Novo submission to the FDA. We are now seeking the right investors to join our mission as Otolith prepares to introduce the first therapeutic device for vestibular migraine patients," said Dan Wagner, Otolith’s COO & CCO.

Sincere thanks to MedTech Innovator for the stage to present our vision to both longtime collaborators and meaningful new connections, as well as to Wilson Sonsini Goodrich & Rosati for hosting such an energizing event.

We were also incredibly grateful to have connected with our trusted advisors, Renee Ryan and Raphael Michel, as well as fellow MedTech Innovator companies!

06/04/2025

Meet us in San Francisco! Otolith Labs is thrilled to join the world’s top medtech innovators at Wilson Sonsini Goodrich & Rosati’s 2025 Medical Device & Digital Health Conference.

Our Founder & CEO Sam Owen, and COO & CCO Dan Wagner will be on-site June 5-6, meeting with leading medtech and healthcare investors. With major milestones accomplished and our FDA Breakthrough-Designated device advancing quickly toward commercialization, we’re at a pivotal moment and eager to share what’s ahead.

Attending ? Let’s connect. Reach out to Sam Owen or Dan Wagner, and we’d love to schedule time to discuss Otolith’s ground-breaking progress and offer an in-person demonstration of our device.

05/19/2025

7 Million people in the U.S. live with vestibular migraines (VM), a condition that can significantly disrupt balance, vision, and everyday life.

Despite its impact, VM is underdiagnosed, often misunderstood, and long overdue for additional solutions. The Otolith team is working hard to change that.

Living with a chronic condition can also increase the risk of mental health challenges, such as anxiety or depression.

This May, we’re proud to support Mental Health Awareness Month by developing therapies designed to restore hope and quality of life.

04/10/2025

📣 Greater Los Angeles residents! Do you have vestibular migraines?

We're actively recruiting for a paid Vestibular Migraine Study in Beverly Hills, CA.

The Dizzy & Vertigo Institute of Los Angeles is conducting a clinical study testing Otolith’s investigational wearable device for vestibular migraines.

Study duration: 1 hour
Compensation: Up to $160

Your participation gives you the opportunity to play an essential role in helping advance research and be part of cutting-edge innovation in the field.

Learn more and see if you qualify (in under >5 minutes) here: https://otolithlabs.com/vestibular-migraine-study/

11/21/2024

Congratulations to Otolith’s Member, Jeffrey Sharon, MD, for his publication as a senior author: “Minimal Clinically Important Difference of Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI)”!

This pioneering new scale is a validated measure of disease-related suffering specific to patients diagnosed with .

VM-PATHI is a tool Otolith uses in our current at-home vestibular migraine study. The patient assessment tool is the first to explicitly address the vestibular migraine population, helping to assess changes in their condition.

We’re proud to work with the top and in the vestibular field and honored to work with Dr. Sharon and our MAB to help address the millions of Americans suffering from vestibular migraines.

Publication Link:

Patients with VM are likely to demonstrate clinical improvement if their VM-PATHI score decreases by 6 or more.

11/21/2024

AAO 2024 was a huge success! The energy at Otolith’s booth was electric and inspiring all week. Our team had the pleasure of connecting with hundreds of clinicians, strategics, and potential users in the field and community.

Thank you to everyone who stopped by to learn about involvement in our vestibular migraine studies, meet our team, and get a closer look at our technology. was filled with meaningful conversations and exciting new partnerships.

Otolith looks forward to turning our clinical progress into regulatory filings to bring this to the incredible American Academy of Otolaryngology—Head and Neck Surgery practitioners and the patients they serve.

09/28/2024

Otolith labs is at ! Stop by Booth 2113 to learn more about clinician involvement in our ongoing hashtag migraine studies, see our product, and connect with our team.

American Academy of Otolaryngology—Head and Neck Surgery

09/06/2024

Otolith Labs is honored to announce we have joined the Vestibular Disorders Association (VEDA)’s Industry Advisory Council!

“The newly formed Industry Advisory Council (IAC) brings together organizations that support , offering strategic advice to VeDA’s leadership to enhance and efforts. The IAC aims to empower patients with vestibular disorders by advocating for advancements that reduce the diagnostic journey and improve their quality of life.”

Otolith Labs is a proud sponsor of VeDa and is excited about this opportunity to collaborate further to support vestibular patients worldwide. Stay tuned for more on Balance Awareness Week Sept. 15-21, 2024!

Read more here: https://vestibular.org/blog/veda-creates-industry-advisory-council/

06/12/2024

Meet us in San Francisco! Sam Owen, Otolith Labs' Founder and CEO, is attending Wilson Sonsini Goodrich & Rosati's 31st Annual Medical Device Digital Health Conference this Thursday and Friday, June 13-14, 2024.

Contact Sam Owen if you are attending. We're eager to share the latest updates on major milestones at Otolith, study results, and demonstrate our breakthrough device in development for treating chronic .

Looking forward to meeting with key leaders in the and market.